XOMA saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on February 19, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 57 instances where the indicator turned negative. In of the 57 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on February 19, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on XOMA as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 50-day moving average for XOMA moved below the 200-day moving average on February 13, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XOMA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for XOMA entered a downward trend on January 22, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for XOMA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XOMA advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .
XOMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.271) is normal, around the industry mean (12.496). P/E Ratio (0.000) is within average values for comparable stocks, (84.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). XOMA has a moderately high Dividend Yield (0.020) as compared to the industry average of (0.012). P/S Ratio (28.090) is also within normal values, averaging (251.218).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XOMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XOMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a developer of pharmaceutical preparations
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
MMKBX | 21.66 | N/A | N/A |
Morgan Stanley Inst Emerging Mkts A | |||
TNVIX | 17.43 | N/A | N/A |
1290 GAMCO Small/Mid Cap Value I | |||
BIDEX | 10.45 | -0.03 | -0.29% |
BlackRock Defensive Advantage EM Instl | |||
VGINX | 87.02 | -1.15 | -1.30% |
JPMorgan US Value R6 | |||
MUEUX | 36.53 | -0.64 | -1.72% |
MFS Blended Research Core Equity R4 |
A.I.dvisor tells us that XOMA and LYEL have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XOMA and LYEL's prices will move in lockstep.
Ticker / NAME | Correlation To XOMA | 1D Price Change % | ||
---|---|---|---|---|
XOMA | 100% | -4.16% | ||
LYEL - XOMA | 32% Poorly correlated | +6.17% | ||
PRME - XOMA | 32% Poorly correlated | -5.27% | ||
INVA - XOMA | 30% Poorly correlated | +0.06% | ||
CRBU - XOMA | 30% Poorly correlated | -7.09% | ||
FATE - XOMA | 30% Poorly correlated | -8.09% | ||
More |